Subconjunctival Aflibercept for the Treatment of Formed Corneal Neovascularization.
暂无分享,去创建一个
I. Bahar | Y. Nahum | R. Sella | E. Livny | Meydan Ben Ishai | Eitan Livny
[1] Da-Wei Li. Neovascularization , 2020, Definitions.
[2] Pradeep Susvar,et al. Subconjunctival bevacizumab and argon laser photocoagulation for preexisting neovascularization following deep lamellar anterior keratoplasty , 2019, Indian journal of ophthalmology.
[3] I. Bahar,et al. Comparison of Subconjunctival Aflibercept and Betamethasone for the Treatment of Formed Corneal Neovascularization in a Rabbit Model , 2019, Ophthalmic Research.
[4] J. Reidy,et al. Short-term regression of corneal neovascularization with combination therapy of argon green laser photocoagulation and subconjunctival bevacizumab , 2019, International medical case reports journal.
[5] Sibel Aksoy. Treatment of corneal neovascularization with topical aflibercept in a case of exposure keratopathy following cerebellar astrocytoma surgery , 2019, Indian journal of ophthalmology.
[6] E. Holland,et al. Current and emerging therapies for corneal neovascularization. , 2018, The ocular surface.
[7] T. Kadar,et al. Successful single treatment with ziv‐aflibercept for existing corneal neovascularization following ocular chemical insult in the rabbit model , 2018, Experimental eye research.
[8] C. Cursiefen,et al. Fine Needle-Diathermy Regresses Pathological Corneal (Lymph)Angiogenesis and Promotes High-Risk Corneal Transplant Survival , 2018, Scientific Reports.
[9] K. Yoon,et al. Effectiveness of photodynamic therapy with verteporfin combined with intrastromal bevacizumab for corneal neovascularization in Stevens–Johnson syndrome , 2019, International Ophthalmology.
[10] T. Das,et al. Intravitreal Ziv‐Aflibercept: Clinical Effects and Economic Impact , 2017, Asia-Pacific journal of ophthalmology.
[11] M. Shahsuvaryan. Therapeutic Potential of Ranibizumab in Corneal Neovascularization. , 2017, Trends in pharmacological sciences.
[12] Chan Hee Moon,et al. Comparison of Topical Low-Molecular-Weight Heparin–Taurocholate and Bevacizumab for Treatment and Prevention of Corneal Neovascularization , 2017, Cornea.
[13] M. Kim,et al. Effects of Combined Photodynamic Therapy and Topical Bevacizumab Treatment on Corneal Neovascularization in Rabbits , 2016, Cornea.
[14] D. Weinberger,et al. Efficacy of Subconjunctival Aflibercept Versus Bevacizumab for Prevention of Corneal Neovascularization in a Rat Model , 2016, Cornea.
[15] T. B. Ali,et al. [Management of corneal neovascularization prior to corneal transplantation: Report of 112 cases]. , 2016, Journal francais d'ophtalmologie.
[16] D. Weinberger,et al. Efficacy of topical aflibercept versus topical bevacizumab for the prevention of corneal neovascularization in a rat model. , 2016, Experimental eye research.
[17] C. Willoughby,et al. Method for Angiographically Guided Fine-Needle Diathermy in the Treatment of Corneal Neovascularization , 2016, Cornea.
[18] Q. Nguyen,et al. Aflibercept for neovascular age-related macular degeneration. , 2016, The Cochrane database of systematic reviews.
[19] K. Mireskandari,et al. Corneal Fine Needle Diathermy With Adjuvant Bevacizumab to Treat Corneal Neovascularization in Children , 2015, Cornea.
[20] A. Mansour,et al. Ziv-aflibercept in macular disease , 2015, British Journal of Ophthalmology.
[21] Chung-Tien Lin,et al. Mechanisms Controlling the Effects of Bevacizumab (Avastin) on the Inhibition of Early but Not Late Formed Corneal Neovascularization , 2014, PloS one.
[22] A. Loewenstein,et al. High-Dose Topical Bevacizumab for Corneal Neovascularization , 2013, Pharmacology.
[23] F. Parmeggiani,et al. Aflibercept in wet AMD: specific role and optimal use , 2013, Drug design, development and therapy.
[24] R. Dana,et al. Topical Ranibizumab as a Treatment of Corneal Neovascularization , 2013, Cornea.
[25] A. Galor,et al. Single and multiple injections of subconjunctival ranibizumab for early, recurrent pterygium , 2013, Clinical ophthalmology.
[26] D. Azar,et al. Corneal neovascularization: an anti-VEGF therapy review. , 2012, Survey of ophthalmology.
[27] R. Forte,et al. Effects of subconjunctival bevacizumab on corneal neovascularization: results of a prospective study , 2012, Cornea.
[28] M. Stewart. Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept , 2012, Clinical ophthalmology.
[29] I. Bahar,et al. Anterior segment uses of bevacizumab , 2012, Current opinion in ophthalmology.
[30] J. Jeong,et al. Compensatory Growth Factor and Cytokine Response in Tears After Subconjunctival Bevacizumab Injection , 2011, Cornea.
[31] S. Yeung,et al. Combined Use of Subconjunctival and Intracorneal Bevacizumab Injection for Corneal Neovascularization , 2011, Cornea.
[32] R. Dana,et al. Consensus statement on indications for anti-angiogenic therapy in the management of corneal diseases associated with neovascularisation: outcome of an expert roundtable , 2011, British Journal of Ophthalmology.
[33] Seungbum Kang,et al. The Effect of Subconjuctival Combined Treatment of Bevacizumab and Triamcinolone Acetonide on Corneal Neovascularization in Rabbits , 2010, Cornea.
[34] P. Vassileva,et al. Avastin use in high risk corneal transplantation , 2009, Graefe's Archive for Clinical and Experimental Ophthalmology.
[35] R. Dana,et al. Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. , 2009, Archives of ophthalmology.
[36] A. Kheirkhah,et al. Temporary sutureless amniotic membrane patch for acute alkaline burns. , 2008, Archives of ophthalmology.
[37] H. Tchah,et al. The effect of topical bevacizumab on corneal neovascularization. , 2008, Ophthalmology.
[38] I. Bahar,et al. Subconjunctival Bevacizumab Injection for Corneal Neovascularization , 2008, Cornea.
[39] K. Bartz-Schmidt,et al. Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn , 2007, Acta ophthalmologica.
[40] Björn Bachmann,et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. , 2007, Investigative ophthalmology & visual science.
[41] D. Azar. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). , 2006, Transactions of the American Ophthalmological Society.
[42] B. Rouse,et al. Contribution of Vascular Endothelial Growth Factor in the Neovascularization Process during the Pathogenesis of Herpetic Stromal Keratitis , 2001, Journal of Virology.